The DOI matches its Crossref record; 31 of the 31 references it cites were found in a registry or an index.
A Common Mechanism Underlying Promiscuous Inhibitors from Virtual and High-Throughput Screening
Open accessAbstract
High-throughput and virtual screening are widely used to discover novel leads for drug design. On examination, many screening hits appear non-drug-like: they act noncompetitively, show little relationship between structure and activity, and have poor selectivity. Attempts to develop these peculiar molecules into viable leads are often futile, and much time can be wasted on the characterization of these "phony" hits. Despite their common occurrence, the mechanism of action of these promiscuous molecules remains unknown. To investigate this problem, 45 diverse screening hits were studied. Fifteen of these were previously reported as inhibitors of various receptors, including beta-lactamase, malarial protease, dihydrofolate reductase, HIV Tar RNA, thymidylate synthase, kinesin, insulin receptor, tyrosine kinases, farnesyltransferase, gyrase, prions, triosephosphate isomerase, nitric oxide synthase, phosphoinositide 3-kinase, and integrase; 30 were from an in-house screening library of a major pharmaceutical company. In addition to their original targets, 35 of these 45 compounds were shown to inhibit several unrelated model enzymes. These 35 screening hits included compounds, such as fullerenes, dyes, and quercetin, that have repeatedly shown activity against diverse targets. When tested against the model enzymes, the compounds showed time-dependent but reversible inhibition that was dramatically attenuated by albumin, guanidinium, or urea. Surprisingly, increasing the concentration of the model enzymes 10-fold largely eliminated inhibition, despite a 1000-fold excess of inhibitor; a well-behaved competitive inhibitor did not show this behavior. One model to explain these observations was that the active form of the promiscuous inhibitors was an aggregate of many individual molecules. To test this hypothesis, light scattering and electron microscopy experiments were performed. The nonspecific inhibitors were observed to form particles of 30-400 nm diameter by both techniques. In control experiments, a well-behaved competitive inhibitor and an inactive dye-like molecule were not observed to form aggregates. Consistent with the hypothesis that the aggregates are the inhibitory species, the particle size and IC(50) values of the promiscuous inhibitors varied monotonically with ionic strength; a competitive inhibitor was unaffected by changes in ionic strength. Unexpectedly, aggregate formation appears to explain the activity of many nonspecific inhibitors and may account for the activity of many promiscuous screening hits. Molecules acting via this mechanism may be widespread in drug discovery screening databases. Recognition of these compounds may improve screening results in many areas of pharmaceutical interest.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Lipinski, C. A., Lombardo, F., Dominy, B. W., & Feeney, P. J. (2001) · Advanced Drug Delivery Reviews · doi:10.1016/s0169-409x(00)00129-0 · Cited by 18,139
Lipinski, C. A., Lombardo, F., Dominy, B. W., & Feeney, P. J. (1997) · Advanced Drug Delivery Reviews · doi:10.1016/s0169-409x(96)00423-1 · Cited by 11,385
The Hydrophobic Effect: Formation of Micelles and Biological Membranes
Tanford, C. (1991) · Medical Entomology and Zoology · Cited by 3,327
Specificity and mechanism of action of some commonly used protein kinase inhibitors
DAVIES, S. P., REDDY, H., CAIVANO, M., & COHEN, P. (2000) · Biochemical Journal · doi:10.1042/bj3510095 · Cited by 3,132
Simple Selection Criteria for Drug-like Chemical Matter
Muegge, I., Heald, S. L., & Brittelli, D. (2001) · Journal of Medicinal Chemistry · doi:10.1021/jm015507e · Cited by 1,315
Walters, W. P., Stahl, M. T., & Murcko, M. A. (1998) · Drug Discovery Today · doi:10.1016/s1359-6446(97)01163-x · Cited by 991
Structure-Based Strategies for Drug Design and Discovery
Kuntz, I. D. (1992) · Science · doi:10.1126/science.257.5073.1078 · Cited by 989
Sun, L., Tran, N., Tang, F., App, H., Hirth, P., McMahon, G., & Tang, C. (1998) · Journal of Medicinal Chemistry · doi:10.1021/jm980123i · Cited by 489
Boehm, H.-J., Boehringer, M., Bur, D., Gmuender, H., Huber, W., Klaus, W., Kostrewa, D., Kuehne, H., Luebbers, T., Meunier-Keller, N., et al. (2000) · Journal of Medicinal Chemistry · doi:10.1021/jm000017s · Cited by 375
Reactive compounds and in vitro false positives in HTS
Rishton, G. M. (1997) · Drug Discovery Today · doi:10.1016/s1359-6446(97)01083-0 · Cited by 351
Structure-Based Discovery of Inhibitors of Thymidylate Synthase
Shoichet, B. K., Stroud, R. M., Santi, D. V., Kuntz, I. D., & Perry, K. M. (1993) · Science · doi:10.1126/science.8451640 · Cited by 322
Self-citationFlexible ligand docking using conformational ensembles
Lorber, D. M., & Shoichet, B. K. (1998) · Protein Science · doi:10.1002/pro.5560070411 · Cited by 295
Self-citationEducation reforms struggle against apartheid's legacy
(1996) · Nature · doi:10.1038/384014a0 · Cited by 291
Inhibitors of human immunodeficiency virus integrase.
Fesen, M. R., Kohn, K. W., Leteurtre, F., & Pommier, Y. (1993) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.90.6.2399 · Cited by 277
Ring, C. S., Sun, E., McKerrow, J. H., Lee, G. K., Rosenthal, P. J., Kuntz, I. D., & Cohen, F. E. (1993) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.90.8.3583 · Cited by 267
Recognizing molecules with drug-like properties
Walters, W. P., Murcko, A. A., & Murcko, M. A. (1999) · Current Opinion in Chemical Biology · doi:10.1016/s1367-5931(99)80058-1 · Cited by 266
Supramolecular Structure of Precipitated Nanosize β ‐Carotene Particles
Auweter, H., Haberkorn, H., Heckmann, W., Horn, D., Lüddecke, E., Rieger, J., & Weiss, H. (1999) · Angewandte Chemie International Edition · doi:10.1002/(sici)1521-3773(19990802)38:15<2188::aid-anie2188>3.0.co;2-# · Cited by 257
DesJarlais, R. L., Seibel, G. L., Kuntz, I. D., Furth, P. S., Alvarez, J. C., Ortiz de Montellano, P. R., DeCamp, D. L., Babé, L. M., & Craik, C. S. (1990) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.87.17.6644 · Cited by 253
Schevitz, R. W., Bach, N. J., Carlson, D. G., Chirgadze, N. Y., Clawson, D. K., Dillard, R. D., Draheim, S. E., Hartley, L. W., Jones, N. D., Mihelich, E. D., et al. (1995) · Nature Structural & Molecular Biology · doi:10.1038/nsb0695-458 · Cited by 216
Deficiency in Rhabdomyosarcomas of a Factor Required for MyoD Activity and Myogenesis
Tapscott, S. J., Thayer, M. J., & Weintraub, H. (1993) · Science · doi:10.1126/science.8383879 · Cited by 213
The inhibition of phosphatidylinositol 3-kinase by quercetin and analogs
Matter, W. F., Brown, R. F., & Vlahos, C. J. (1992) · Biochemical and Biophysical Research Communications · doi:10.1016/0006-291x(92)90792-j · Cited by 196
Ligand binding to proteins: The binding landscape model
Miller, D. W., & Dill, K. A. (1997) · Protein Science · doi:10.1002/pro.5560061011 · Cited by 178
Structure-Based Enhancement of Boronic Acid-Based Inhibitors of AmpC β-Lactamase
Weston, G. S., Blázquez, J., Baquero, F., & Shoichet, B. K. (1998) · Journal of Medicinal Chemistry · doi:10.1021/jm980343w · Cited by 142
Self-citationSuccessful Virtual Screening of a Chemical Database for Farnesyltransferase Inhibitor Leads
Perola, E., Xu, K., Kollmeyer, T. M., Kaufmann, S. H., Prendergast, F. G., & Pang, Y. (2000) · Journal of Medicinal Chemistry · doi:10.1021/jm990408a · Cited by 128
Patera, A., Blaszczak, L. C., & Shoichet, B. K. (2000) · Journal of the American Chemical Society · doi:10.1021/ja001676x · Cited by 98
Self-citationThe complexed structure and antimicrobial activity of a non‐β‐lactam inhibitor of AmpC β‐lactamase
Powers, R. A., Blázquez, J., Weston, G. S., Shoichet, B. K., Morosini, M.-I., & Baquero, F. (1999) · Protein Science · doi:10.1110/ps.8.11.2330 · Cited by 82
Self-citationInhibitors of Kinesin Activity from Structure-Based Computer Screening
Hopkins, S. C., Vale, R. D., & Kuntz, I. D. (2000) · Biochemistry · doi:10.1021/bi992474k · Cited by 81
The application of high-throughput screening to novel lead discovery
Kenny, B. A., Bushfield, M., Parry-Smith, D. J., Fogarty, S. W., & Treherne, J. M. (1998) · Birkhäuser Basel eBooks · doi:10.1007/978-3-0348-8845-5_7 · Cited by 71
Inhibition of Nitric Oxide Synthase Isoforms by Tris-Malonyl-C60-Fullerene Adducts
Wolff, D. J., Papoiu, A. D. P., Mialkowski, K., Richardson, C. F., Schuster, D. I., & Wilson, S. R. (2000) · Archives of Biochemistry and Biophysics · doi:10.1006/abbi.2000.1843 · Cited by 59
X‐ray structure of a novel matrix metalloproteinase inhibitor complexed to stromelysin
Dunten, P., Kammlott, U., Crowther, R. L., Levin, W., Foley, L. H., Wang, P., & Palermo, R. E. (2001) · Protein Science · doi:10.1110/ps.48401 · Cited by 56
Su, A. I., Lorber, D. M., Weston, G. S., Baase, W. A., Matthews, B. W., & Shoichet, B. K. (2000) · Proteins Structure Function and Bioinformatics · doi:10.1002/1097-0134(20010201)42:2<279::aid-prot150>3.0.co;2-u · Cited by 55
Self-citation
Cited by
Network pharmacology: the next paradigm in drug discovery
Hopkins, A. L. (2008) · Nature Chemical Biology · doi:10.1038/nchembio.118 · Cited by 4,622
Small-molecule inhibitors of protein–protein interactions: progressing towards the dream
Arkin, M. R., & Wells, J. A. (2004) · Nature Reviews Drug Discovery · doi:10.1038/nrd1343 · Cited by 1,705
Virtual screening of chemical libraries
Shoichet, B. K. (2004) · Nature · doi:10.1038/nature03197 · Cited by 1,425
Self-citationThe role of natural product chemistry in drug discovery
Butler, M. S. (2004) · Journal of Natural Products · doi:10.1021/np040106y · Cited by 1,381
Challenges of Antibacterial Discovery
Silver, L. L. (2011) · Clinical Microbiology Reviews · doi:10.1128/cmr.00030-10 · Cited by 1,376
Metadata
- Authors
- McGovern, S. L., Caselli, E., Grigorieff, N., & Shoichet, B. K.
- Venue
- Journal of Medicinal Chemistry
- Publisher
- American Chemical Society (ACS)
- Published
- 2002-03-09
- Volume
- 45
- Issue
- 8
- Pages
- 1712-1722
- ISSN
- 0022-2623 (ISSN-L)
- 1520-4804
- OpenAlex
- W2127287358
- Cited by
- 1,042
- References
- 31
- FWCI
- 53.12
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.